IP Verse

Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound - EP3260117

The patent EP3260117 was granted to Amgen on Nov 27, 2019. The application was originally filed on Sep 10, 2004 under application number EP17185704A. The patent is currently recorded with a legal status of "Revoked".

EP3260117

AMGEN
Application Number
EP17185704A
Filing Date
Sep 10, 2004
Status
Revoked
Aug 6, 2024
Grant Date
Nov 27, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PUREN PHARMAMay 25, 2021HAMM & WITTKOPPINTERVENTION ADMISSIBLE
ARISTO PHARMAApr 14, 2021GILLE HRABAL PARTNERSCHAFTSGESELLSCHAFT MBB PATENTANWALTEINTERVENTION ADMISSIBLE
TAD PHARMAMar 8, 2021HOEFER & PARTNER PATENTANWALTE MBBINTERVENTION ADMISSIBLE
BETAPHARM ARZNEIMITTELNov 24, 2020HAMM & WITTKOPPINTERVENTION ADMISSIBLE
AECHTERJan 17, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
BIOGARANJan 17, 2020CASALONGAADMISSIBLE
HGFJan 17, 2020HGFADMISSIBLE
ACCORD HEALTHCAREJan 17, 2020TER MEER STEINMEISTER & PARTNERWITHDRAWN
GLENMARK PHARMACEUTICALS EUROPEJan 16, 2020SCHLICHADMISSIBLE
TEVA PHARMACEUTICALSJan 14, 2020ELKINGTON AND FIFEWITHDRAWN

Patent Citations (36) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0933354
DESCRIPTIONUS2002107406
DESCRIPTIONUS5981599
DESCRIPTIONUS6001884
DESCRIPTIONUS6011068
DESCRIPTIONUS6031003
DESCRIPTIONUS6172091
DESCRIPTIONUS6211244
DESCRIPTIONUS6313146
DESCRIPTIONUS6342532
DESCRIPTIONUS6363231
DESCRIPTIONUS6432656
DESCRIPTIONWO0134562
DESCRIPTIONWO9304373
DESCRIPTIONWO9418959
DESCRIPTIONWO9511221
DESCRIPTIONWO9612697
DESCRIPTIONWO9741090
OPPOSITIONEP0124027
OPPOSITIONEP0315249
OPPOSITIONEP0357815
OPPOSITIONEP0759296
OPPOSITIONEP1663182
OPPOSITIONEP1875495
OPPOSITIONEP2316442
OPPOSITIONEP2821067
OPPOSITIONEP3260117
OPPOSITIONEP3395338
OPPOSITIONEP3395339
OPPOSITIONEP3395340
OPPOSITIONEP3578175
OPPOSITIONUS03502219P
OPPOSITIONUS6211244
OPPOSITIONWO03086343
OPPOSITIONWO2005034928
SEARCHUS6211244

Non-Patent Literature (NPL) Citations (63) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BERGE et al., J. Pharm. Sci., (19770000), vol. 66, no. 1, pages 1 - 19-
OPPOSITION- 14.4 Magnesiumstearat, pages 247 - 250-
OPPOSITION- A. Gennaro, "Oral Dosage Forms, section Disintegrants", Remington - The Science and Practice of Pharmacy, (20000000), vol. 1, pages 1 - 862, XP055673031-
OPPOSITION- A. LE HIR, "Abrégé de pharmacie galénique formes pharmaceutiques", Abrégé de pharmacie galénique formes pharmaceutiques, (19810000), XP055673484-
OPPOSITION- A.L. NEGRI, "Agentes Calciomiméticos en el Tratamento del Hiperparatiroidismo Primario y Secundario", REEMO, (20030700), vol. 12, no. 4, pages 83 - 86, XP055790209-
OPPOSITION- Anonymous, "Amgen Submitted New Drug Application for Cinacalcet HCl", Amgen News Release, (20030908), XP002313388-
OPPOSITION- Anonymous, "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis", ClinicalTrials.gov /NCT00042653/, ClinicalTrials.gov /NCT00042653/, URL: https://clinicaltrials.gov/ct2/show/NCT00042653, (20200226), XP055671896-
OPPOSITION- Anonymous, "Chemistry Review(s)", Center for Drug Evaluation and Research Application Number: 21-688, page 22pp, Center for Drug Evaluation and Research Application Number: 21-688, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Chemr.pdf, (20200226), XP055671894-
OPPOSITION- Anonymous, "Clinical Pharmacology and Biopharmaceutics Review. Application Number 21-688", Center for Drug Evaluation and Research, (20030905), pages 1 - 53, XP055673474-
OPPOSITION- Anonymous, "Expérimental Report II on samples preparations on cinacalcet", Cinacalcet, (20180529), pages 1 - 2, XP055673488-
OPPOSITION- Anonymous, "Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms", FDA, (19970800), pages 1 - 17, XP055253855-
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO Drug Information /Proposed INN :List 88, (20030309), vol. 17, no. 1, pages 41 - 77, XP055790211-
OPPOSITION- Anonymous ·, "Schutt- und Stampfdichte von Pulveren", PH. EUR 10, (20200101), PH. EUR 10, (20220929), XP055966406-
OPPOSITION- Anonymus, "Clinical Pharmacology and Biopharmaceutics Review. Application Number 21-688", Center for Drug Evaluation and Research,, (20030905), pages 1 - 51, XP055673474-
OPPOSITION- "Arzneiformenlehre Ein Lehrbuch der Galenik für Theorie und Praxis /Passage/", Ursula Schöffling, Arzneiformenlehre Ein Lehrbuch der Galenik für Theorie und Praxis, Stuttgart, Deutscher Apotheker Verlag,, (19980000), pages 1pp, 188 - 189, XP055658297-
OPPOSITION- AULTON AULTON, "Factors influencing bioavailability: factors influencing drug absorption from the gastrointestinal tract", PHARMACEUTICS :THE SCIENCE OF DOSAGE FORM DESIGN, (19880000), pages 135, 156 - 157, XP055673473-
OPPOSITION- AULTON, "Chapter 18. Tablets", Pharmaceutics: The Science of Dosage Form Design, (19880000), pages 304 - 305, XP055673010-
OPPOSITION- AULTON M.E, "Chapter 18: Tablets. Tablet formulation", Pharmaceutics: The Science of Dosage Form Design, New York, (19880000), pages 311 - 312, XP05567302-
OPPOSITION- AULTON, "Pharmaceutics: The Science of Dosage Form Design", Pharmaceutics: The Science of Dosage Form Design, (20020000), pages 404 - 408, XP055673015-
OPPOSITION- A. Wade et al, "Microcrystalline Cellulose / Crospovidone / Pregelatinized Starch", Handbook of pharmaceutical excipients, 2nd ed, (19940101), pages 84 - 143-144 491- 493, XP055673621-
OPPOSITION- BANAKAR, "Factors That Influence Dissolution Testing", Pharmaceutical Dissolution Testing, (19920000), pages 136, 137 - 144, 145, XP055308585-
OPPOSITION- BANAKAR, "Factors That Influence Dissolution Testing", Pharmaceutical Dissolution Testing, (19920000), pages 136, 137, - 144, 145, XP055308585-
OPPOSITION- "CHAPTER 38, 45", Remington: The Science and Practice of Pharmacy 20th edition, (20000000), pages 704, 858 - 893, XP055672929-
OPPOSITION- "Chapter 5 and 6", Gennaro, Remington - The Science and Practice of Pharmacy, (20000000), vol. 1, pages 865 - 869, XP055673556-
OPPOSITION- "Commonly used excipients in granulation", Handbook of Granulation technology, (19970000), pages 51 - 52, XP055673586-
OPPOSITION- "Dissolution", Anonymous, Remington - The Science and Practice of Pharmacy, (20000000), vol. 1, pages 657 - 658, XP055673565-
OPPOSITION- Eugene F. Fiese et al, "Preformulation", The Theory and Practice of Industrial Pharmacy, Third Edition, Lea & Febiger, (19870101), pages 171 - 303, XP055671875-
OPPOSITION- Fda, "Drug approval Package: Sensipar (Cinacalcet HCI) NDA #021688", URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688_Sensipar.cfm, (20200304), XP055673613-
OPPOSITION- Gennaro Alfonso, "Chapter 38, 45", Remington: The Science and Practice of Pharmacy 20th edition, vol. 704, (20000000), vol. 704, pages 858 - 893, XP055672929-
OPPOSITION- GIBALDI, "Biopharmaceutics and Clinical Pharmaceutics", Biopharmaceutics and Clinical Pharmaceutics, (19910000), page 51, XP055673477-
OPPOSITION- GOODMAN WILLIAM G et al., "The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism", Journal of the American Society of Nephrology, (20020000), vol. 13, no. 4, pages 1017 - 1024, XP002387352-
OPPOSITION- "Handbook of Pharmaceutical excipients", Handbook of Pharmaceutical excipients, (20000000), pages 102-103, 143,163-164, 306, 433 - 528-529, XP055673604-
OPPOSITION- J.C CHAUMEIL, "Micronisation : a method for improving the bioavailability of poorly soluble drugs", Meth Find Clin. Pharmacol, (19980000), pages 211 - 215, XP055673475-
OPPOSITION- LACHMAN et al., "The Theory and Practice of Industrial Pharmacy THIRD EDITION", The Theory and Practice of Industrial Pharmacy THIRD EDITION, (19860000), pages 189, 321, 324 - 329, XP055672926-
OPPOSITION- LACHMAN et al., "The Theory and Practice of Industrial Pharmacy", Varghese Publishing House. Third Ed., (19860000), pages 189, 321, 324 - 329, XP055673018-
OPPOSITION- LIEBERMAN, "Chapter 3, and 4", Pharmaceutical dosage forms: Tablets vol 1, second edition, (19900000), vol. 131, 246, XP055672944-
OPPOSITION- LIEBERMAN et al., "Chapter 1 - Preformulation Testing", Pharmaceutical Dosage Forms: Tablets, Volume 1, 2nd ed., (19890000), pages 1 - 24, XP055416092-
OPPOSITION- LIEBERMAN et al., "Chapter 3, and 4", Pharmaceutical dosage forms: Tablets vol 1, second edition, (19900000), vol. 131, 246, XP055672944-
OPPOSITION- Limdberg Jill S, Et Al., "Cinacalcet HCI, an oral Calcimimetic agent for the treatment of secondary hyperparathyroidism in hemoddialysis and peritoneal dialysis: A randomized, double-blind , multicenter study", American Society of Nephrology, (20050101), vol. 16, XP055966686-
OPPOSITION- L. LACHMAN et al., "The theory and Practice of Industrial Pharmacy", Varghese Publishing House. Third Ed., (19860000), pages 324 - 328, XP055673018-
OPPOSITION- MEEUS, "Optimisation of excipient blends in tablet formulations by experimental designs", Pharma Chem, (20020000), pages 37 - 41, XP055672958-
OPPOSITION- "Mikrokristalline Cellulose", Anonymous, Europäisches Arzneibuch 4. Ausgabe, Grundwerk 2002 (Ph.Eur. 4.00), Deutscher Apotheker Verlag, (2002), page 1460-1461, 1607-1608, 2717-2720, 2859, 2899, XP055790199-
OPPOSITION- Milo Gibaldi, "Biopharmaceutics and Clinical Pharmacokinetics, fourth edition", Biopharmaceutics and Clinical Pharmacokinetics, fourth edition, Lea& Febiger, (19910101), page 2pp, 51, ISBN 978-0-8121-1346-4, XP055282823-
OPPOSITION- ROWE et al., "Cellulose, microcrystalline", Handbook of Pharmaceutical Excipients, (20030529), pages 108 - 111, 603-611, XP055672961-
OPPOSITION- Rowe Raymond, "Handbook of Pharmaceutical Excipients sixth edition", Handbook of Pharmaceutical Excipients sixth edition, (20090000), pages 685 - 690, XP055673609-
OPPOSITION- VOIGT, "Kapitel 9", Pharmazeutische Technologie, (20000000), pages 163 - 187, XP055672956-
OPPOSITION- VOIGT, "Pharmazeutische Technologie für studium und beruf", Pharmazeutische Technologie, (20000000), pages 163 - 187, XP055672956-
OPPOSITION- WAN et al., "Action of carriers on drug dissolution", S.T.P. Pharma Sciences, (19950000), vol. 5, pages 134 - 138, XP055672932-
OPPOSITION- QURESHI SA et al., "Cause of high variability in drug dissolution testing and its impact on setting tolerances", Eur J Pharm Sci., (20010000), vol. 12, pages 271 - 276, XP055673539
OPPOSITION- K. L. Andrew Chan,T Stephen V. Hammond, and Sergei G. Kazarian, "Applications of Attenuated Total Reflection Infrared Spectroscopic Imaging to Pharmaceutical Formulations", Anal.Chem, (2003), vol. 75, pages 2140 - 2146, XP001170728
OPPOSITION- QUARLES, L.D. et al., "The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease", Am Soc Nephrol, (20030300), vol. 14, pages 575 - 583, XP055671891
OPPOSITION- FRANCE SCHINI et al., "Cinacalcet HCI: a calcimetric agent for the management of primary and secondary hyperparathyroidism", Expert Opin Investig Drugs, (20030800), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, pages 1413 - 21, XP009083254
OPPOSITION- FRANCE SCHINI et al., "Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin. Investig. Drugs, (20030000), vol. 12, doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCE SCHINI et al., "Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism", Expert Opin. Investig. Drugs, (20030000), vol. 12, doi:10.1517/13543784.12.8.1413, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCESCHINI N. et al, "CINACALCET HCI: A CALCIMIMETIC AGENT FOR THE MANAGEMENT OF PRIMARY AND SECONDARY HYPERPARATHYROIDISM", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK, (20030101), vol. 12, no. 8, doi:10.1517/13543784.12.8.1413, ISSN 1354-3784, pages 1413 - 1421, XP009083254
OPPOSITION- FRANCE SCHINI, N et al., "Cinacalcet HCl : a calcimimetic agent for the management of primary and seconda hyperparathyroidism", Expert opin. Investi. Drus, (20030000), vol. 12, no. 8, pages 1413 - 1421, XP009083254
SEARCH- ANONYMOUS, "Amgen submitted new drug application for Cinacalcet HCI", (20030908), AMGEN NEWS RELEASE, URL: http://www.amgen.com/news/news03/pressRelease030908a.pdf, (20050112), XP002313388 [Y] 1-17 * the whole document *-
SEARCH- ANONYMOUS, "FDA Approves First in a New Class of Drugs to Treat Hyperparathyroidism Associated With Renal Failure and in Patients With Parathyroid Cancer", (20040308), FDA TALK PAPER, URL: http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01282.html, (20050111), XP002313389 [YP] 1-17 * the whole document *-
SEARCH- ANONYMOUS, "NPS-Drug Development: Product Develpment Pipeline", (20030908), INTERNET ARTICLE, URL: www.npsp.com/drug_development/pipeline.php, (20050112), XP002313391 [A] 1-17 * the whole document *-
SEARCH- ANONYMOUS, "Sensipar (cinacalcet HCI) Tablets", (20040812), INTERNET ARTICLE, URL: www.rxlist.com/cgi/generic3/sensipar.htm, (20050110), XP002313390 [YP] 1-17 * the whole document *-
SEARCH- GOODMAN WILLIAM G ET AL, "The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN. APR 2002, (200204), vol. 13, no. 4, ISSN 1046-6673, pages 1017 - 1024, XP002313387 [Y] 1-17 * the whole document *-
SEARCH- NEMETH EDWARD F ET AL, "Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. FEB 2004, (200402), vol. 308, no. 2, ISSN 0022-3565, pages 627 - 635, XP009042339 [YP] 1-17 * the whole document *
SEARCH- "Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.", DRUGS IN R&D. 2003, (2003), vol. 4, no. 6, ISSN 1174-5886, pages 349 - 351, XP009042342 [YP] 1-17 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents